These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 34614319)

  • 1. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. Reply.
    O'Brien MP; Hou P; Weinreich DM
    N Engl J Med; 2021 Nov; 385(20):e70. PubMed ID: 34614319
    [No Abstract]   [Full Text] [Related]  

  • 2. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
    Merison T; Goldman A; Bomze D
    N Engl J Med; 2021 Nov; 385(20):e70. PubMed ID: 34614318
    [No Abstract]   [Full Text] [Related]  

  • 3. In uninfected household contacts of patients with COVID-19, REGEN-COV reduced symptomatic COVID-19 at 28 d.
    Lau D; Saxinger L
    Ann Intern Med; 2022 Jan; 175(1):JC5. PubMed ID: 34978854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic.
    Levey NH; Forrest AD; Spielman DW; Easley KA; Dude CM; Badell ML
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100673. PubMed ID: 35671984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes.
    Hayek S; Ben-Shlomo Y; Dagan N; Reis BY; Barda N; Kepten E; Roitman A; Shapira S; Yaron S; Balicer RD; Netzer D; Peretz A
    Nat Commun; 2022 Aug; 13(1):4480. PubMed ID: 35918340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme.
    Ducloux D; Courivaud C
    Kidney Int; 2022 Mar; 101(3):645-646. PubMed ID: 34995651
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19.
    Parums DV
    Med Sci Monit; 2021 Aug; 27():e934393. PubMed ID: 34393218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regen-COV-2 Antibody Cocktail Mediated Clearance of SARS-COV-2 in an Immunocompromised Patient.
    Basheer M; Saad E; Milhem F; Budman D; Assy N
    Isr Med Assoc J; 2022 Nov; 24(11):695-696. PubMed ID: 36436032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders.
    Stein D; Oviedo-Orta E; Kampman WA; McGinniss J; Betts G; McDermott M; Holly B; Lancaster JM; Braunstein N; Yancopoulos GD; Weinreich DM
    Clin Infect Dis; 2022 Aug; 75(1):e509-e515. PubMed ID: 34971385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
    Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
    Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. REGEN-COV antibody combination in patients with lymphoproliferative malignancies and SARS-CoV-2 infection.
    Bronstein Y; Avivi I; Cohen YC; Feigin E; Perry C; Herishanu Y
    EJHaem; 2022 May; 3(2):471-474. PubMed ID: 35602247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal Antibody for Patients with Covid-19. Reply.
    Lundgren JD; Lane HC; Neaton JD
    N Engl J Med; 2021 Mar; 384(12):1171. PubMed ID: 33534968
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

  • 14. REGEN-COV
    Irvin SC; Ganguly S; Weiss R; Elango C; Zhong X; Mao Y; Yan H; Li N; Sumner G; Turner KC; Davis JD; DiCioccio AT; Andisik MD; Partridge MA; Torri A
    Bioanalysis; 2021 Dec; 13(24):1827-1836. PubMed ID: 34743612
    [No Abstract]   [Full Text] [Related]  

  • 15. [SARS-CoV-2 neutralizing monoclonal antibodies: a potential breakthrough in the early treatment of Covid-19 in high-risk patients].
    de Bree GJ; Wiersinga WJ
    Ned Tijdschr Geneeskd; 2021 Oct; 165():. PubMed ID: 34854645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral monoclonal antibody cocktails as a modern weapon in combating pandemics.
    Liu D; Shameem M
    Ther Deliv; 2022 Feb; 13(2):67-69. PubMed ID: 34726506
    [No Abstract]   [Full Text] [Related]  

  • 17. Regen-Cov and Covid-19, Update on the Drug Profile and Fda Status: A Mini-Review and Bibliometric Study.
    Mawazi SM; Khan J; Othman N; Alolayan SO; Alahmadi YM; Thagfan SSA; Helmy SA; Marzo RR
    J Public Health Res; 2022 Apr; 10(2 Suppl):. PubMed ID: 35898931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
    Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
    Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.
    Wolf J; Abzug MJ; Anosike BI; Vora SB; Waghmare A; Sue PK; Olivero RM; Oliveira CR; James SH; Morton TH; Maron GM; Young JL; Orscheln RC; Schwenk HT; Bio LL; Willis ZI; Lloyd EC; Hersh AL; Huskins CW; Soma VL; Ratner AJ; Hayes M; Downes K; Chiotos K; Grapentine SP; Wattier RL; Lamb GS; Zachariah P; Nakamura MM
    J Pediatric Infect Dis Soc; 2022 May; 11(5):177-185. PubMed ID: 35107571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review].
    Chen Y; Lin J; Zheng P; Cao M; Jin T
    Sheng Wu Gong Cheng Xue Bao; 2022 Sep; 38(9):3173-3193. PubMed ID: 36151792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.